Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-- Veterans will have access to GI Genius™ intelligent endoscopy modules across the country that use AI help to detect colorectal polyps during colonoscopy --
-- Among Veterans, Colorectal cancer is of the five most frequently diagnosed cancers and a leading cause of cancer-related deaths --
-- Nexpowder™* provides gastroenterologists improved visibility, controls upper gastrointestinal (GI) bleeding effectively and with ease1,2,3 --
-- Nexpowder™* endoscopic hemostasis system showed a lower rebleeding rate and has nearly double the adhesive force of other hemostatic sprays2,3 --
Medtronic been ranked fifth in the 2022 Best Workplaces in Asia list by Great Place to Work, the global authority on workplace culture. This is a significant improvement of six places from 2021....
Bifurcation using Onyx Frontier DES Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the...
Medtronic announced today that it recently received CE mark for its Radiant™ balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the...
TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...
TCT 2022: Pathological Findings Confirm Importance of Early Detection and Treatment of Thrombus on Valve Leaflets Medtronic today announced findings from its Pathological Study of Hypo-Attenuated...
TCT 2022: Medtronic Unveils Latest Transcatheter Aortic Valve Replacement Data in Late-Breaking Clinical Science and Presentations
George Murgatroyd, general manager and vice president of Digital Surgery at Medtronic, will join Kimberly Powell, vice president of Healthcare and Life Sciences at NVIDIA, in a fireside chat at NVIDIA
Medtronic plc, a global leader in healthcare technology, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for the RespArray™ patient monitor designed for procedural sedation and medical-surgical units.
Combination of InPen™ smart insulin pen system integrated with Guardian™ 4 CGM helps people with diabetes on multiple daily injections (MDI) stay ahead of their glucose levelsi,ii
Partnership enables Patient Monitoring business’ commitment to transforming health monitoring by expanding access to continuous vital sign monitoring of patients from in-hospital to home
Medtronic announced today that it has launched its newest drug-eluting coronary stent, the Onyx Frontier™ drug-eluting stent (DES), following recent CE Mark approval. The Onyx Frontier DES...
Actress Jennifer Stone, best known for her role on the Disney Channel’s “Wizards of Waverly Place”, will be partnering with Medtronic Diabetes to help others living with type 1 diabetes learn more about advanced technologies that can help make life with diabetes easier...
BRAMPTON, July 20, 2022 – Medtronic Canada today announced that Neil Fraser has decided to retire as President of Medtronic Canada ULC and Regional Vice-President, Medtronic plc, effective July...
The Medtronic Foundation launched 10 partnerships with leading equity-based STEM organizations serving students in Southern California, Colorado, and Ireland. Partnerships will remove barriers to quality Science, Technology, Engineering, and Math (STEM) education and create opportunity for economic advancement.
A minimally invasive approach, the ILLUMISITE™ platform navigates accurately to even the most distant areas of the lung, and can sample multi-directionally for a thorough biopsy. Medtronic...
Clinicians now have added ability to personalize care with the integration of two continuous monitoring solutions from Medtronic plc...
Medtronic presence to include 1 3 data presentations, a LinkedIn Livestream featuring Que Dallara, EVP & President, Medtronic Diabetes, comprehensive exhibit booth with presentations and a product theatre
Built on the market-leading IN.PACT™ Admiral™ DCB technology, the IN.PACT™ 018 DCB is engineered to cross tight lesions and designed for better deliverability§
3BL Media has named Medtronic to its annual 100 Best Corporate Citizens ranking, recognizing outstanding environmental, social and governance (ESG) transparency and performance among the 1,000...
Mid-term results of Optimize PRO clinical study reinforces benefits of predictability and control using cusp overlap technique
Prospective study will evaluate the long-term performance of the closed-loop algorithm and overall patient experience with Medtronic’s next generation, rechargeable spinal cord stimulation device
The Hugo™ RAS system has won a “Medical Device Innovation Award” in the 2022 MedTech Breakthrough Awards program. “After more than 20 years of availability, robotic-assisted surgery only...
EXPAND TAVR II Pivotal Trial evaluating the Evolut™ TAVR platform in a new patient population
Heart Rhythm 2022: Sub-analysis indicates patients with intermittent monitoring may not be optimally managed for secondary stroke prevention
Medtronic, the global leader in medical technology, today announced new randomized controlled data demonstrating the sustained and superior performance of IN.PACT AV drug coated balloon (DCB)...
Medtronic today announced that it has signed an agreement with Acutus Medical Inc., a manufacturer of arrhythmia management technologies, for exclusive rights to distribute and acquire its...
Results were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference
Medtronic plc, the global leader in medical technology, today announced its participation at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking...
Medtronic plc, a global leader in healthcare technology, today announced that reimbursement for its advanced insulin delivery system, MiniMed 780G, has been recently expanded across two more...
AccuRhythm AI algorithms shown to reduce false alerts by 84%
ACC.22: Late-breaking data show CoreValve™ and Evolut™ is the only platform to out-perform surgery in valve durability at five years